URMC / Research / Clinical Trials / Study Details

Breast Cancer: MK-3475 as Adjuvant therapy for Triple Receptor-Negative Breast Cancer or Positive Lymph Nodes After Neoadjuvant Chemotherapy - S1418

Research Question:
Does the drug MK-3475 help the survival of patients with breast cancer?

Basic Study Information

Purpose:
The purpose of this study is to compare treated subjects' invasive disease-free survival of patients with triple-negative breast cancer after neoadjuvant chemotherapy.

Location: University of Rochester Medical Center
Study Reference #: CBRS18089

Lead Researcher (Principal Investigator)

Lead Researcher: Alissa Huston

Study Contact Information

Study Coordinator: Laura Mitchell
Phone: (585) 275-7763
Email: Laura_Mitchell@URMC.Rochester.edu

Additional Study Details

Contact This Study

First Name *

This field is required

Middle Name

Last Name *

This field is required

Phone Number

I agree to be contacted by The University of Rochester Medical Center regarding participation in this study. *

You must agree to be contacted to continue.

Please call me during the day.

Please call me during the evening.

Message

Return to Search

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Wilmot Clinical Trials